

1 **IMMUNO-COV™ v2.0: Development and Validation of a High-Throughput**  
2 **Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers**

3 Rianna Vandergaast,<sup>a#</sup> Timothy Carey,<sup>a</sup> Samantha Reiter,<sup>a</sup> Chase Lathrum,<sup>a</sup> Patrycja Lech,<sup>a</sup>  
4 Clement Gnanadurai,<sup>a</sup> Michelle Haselton,<sup>a</sup> Jason Buehler,<sup>a</sup> Riya Narjari,<sup>a</sup> Luke Schnebeck,<sup>a</sup> Anne  
5 Roesler,<sup>a¥</sup> Kara Sevola,<sup>a</sup> Lukkana Suksanpaisan,<sup>a</sup> Alice Bexon,<sup>b</sup> Shruthi Naik,<sup>b,c</sup> Bethany  
6 Brunton,<sup>b†</sup> Scott C. Weaver,<sup>d</sup> Grace Rafael,<sup>d</sup> Sheryl Tran,<sup>b</sup> Alina Baum,<sup>e</sup> Christos A. Kyratsous,<sup>e</sup>  
7 Kah Whye Peng,<sup>a,b,c</sup> and Stephen J. Russell<sup>a,b,c#</sup>

8  
9 <sup>a</sup>Imanis Life Sciences, Rochester, MN 55901

10 <sup>b</sup>Vyriad, Inc., Rochester, MN 55901

11 <sup>c</sup>Mayo Clinic Department of Molecular Medicine, Rochester, MN 55905

12 <sup>d</sup>World Reference Center for Emerging Viruses and Arboviruses, Institute for Human Infections  
13 and Immunity, and Department of Microbiology and Immunology, University of Texas Medical  
14 Branch, Galveston, TX 77555

15 <sup>e</sup>Regeneron Pharmaceuticals Inc., Tarrytown, NY 10591

16  
17 Running title: Development and Validation of IMMUNO-COV™ v2.0

18  
19 #Corresponding authors: Rianna Vandergaast ([vandergaast.rianna@imanislife.com](mailto:vandergaast.rianna@imanislife.com)) and Stephen  
20 J. Russell ([sjrussell@vyriad.com](mailto:sjrussell@vyriad.com))

21  
22 ¥Current address: Mayo Clinic Department of Orthopedic Surgery, Rochester, MN 55902

23 †Current address: Janssen Research & Development, Spring House, PA 19477

24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

## **ABSTRACT**

Neutralizing antibodies are key determinants of protection from future infection, yet well-validated high-throughput assays for measuring titers of SARS-CoV-2-neutralizing antibodies are not generally available. Here we describe the development and validation of IMMUNO-COV<sup>TM</sup> v2.0 a scalable surrogate virus assay, which titrates antibodies that block infection of Vero-ACE2 cells by a luciferase-encoding vesicular stomatitis virus displaying SARS-CoV-2 spike glycoproteins (VSV-SARS2-Fluc). Antibody titers, calculated using a standard curve consisting of stepped concentrations of SARS-CoV-2 spike monoclonal antibody, correlated closely ( $p < 0.0001$ ) with titers obtained from a gold-standard PRNT50% assay performed using a clinical isolate of SARS-CoV-2. IMMUNO-COV<sup>TM</sup> v2.0 was comprehensively validated using data acquired from 242 assay runs performed over seven days by five analysts, utilizing two separate virus lots, and 176 blood samples. Assay performance was acceptable for clinical use in human serum and plasma based on parameters including linearity, dynamic range, limit of blank and limit of detection, dilutional linearity and parallelism, precision, clinical agreement, matrix equivalence, clinical specificity and sensitivity, and robustness. Sufficient VSV-SARS2-Fluc virus reagent has been banked to test 5 million clinical samples. Notably, a significant drop in IMMUNO-COV<sup>TM</sup> v2.0 neutralizing antibody titers was observed over a six-month period in people recovered from SARS-CoV-2 infection. Together, our results demonstrate the feasibility and utility of IMMUNO-COV<sup>TM</sup> v2.0 for measuring SARS-CoV-2-neutralizing antibodies in vaccinated individuals and those recovering from natural infections. Such monitoring can be used to better understand what levels of neutralizing antibodies are required for protection from SARS-CoV-2, and what booster dosing schedules are needed to sustain vaccine-induced immunity.

47

## **INTRODUCTION**

48       On March 11, 2020, the World Health Organization declared COVID-19, caused by SARS-  
49 CoV-2, a pandemic. Since then, the coordinated efforts of numerous researchers, biotechnology  
50 and pharmaceutical companies, contract manufacturers, healthcare organizations, and  
51 governmental agencies have resulted in the approval and initial distribution of the first SARS-  
52 CoV-2 vaccines. Clinical trial data indicate that the vaccines currently approved in the US are  
53 approximately 95% effective at preventing COVID-19 (1,2). However, the durability of this  
54 protection is unknown. Neutralizing antibody responses following vaccination correlate with  
55 protective immunity (3–6), yet an increasing number of studies, including this one, demonstrate  
56 that neutralizing antibody levels fall steadily in the months following natural SARS-CoV-2  
57 infection or vaccination (7–11). Thus, protective antibody responses, including those elicited by  
58 vaccination, may be relatively short-lived, and repeat vaccine dosing over several years may be  
59 necessary to achieve and maintain herd immunity. It is not currently known what titer of  
60 neutralizing antibodies confers protection from SARS-CoV-2 infection or COVID-19. Studies to  
61 monitor neutralizing antibody responses and the associated risk of infection at various timepoints  
62 post-vaccination are needed to inform decisions on the appropriate timing of booster vaccine  
63 doses. To facilitate these studies, a reliable, high-throughput method for quantitatively measuring  
64 neutralizing antibody titers is critically needed.

65       Over the course of the past year, numerous rapid serological tests have been developed, and  
66 many have received Emergency Use Authorization (EUA) approvals for the detection of  
67 antibodies against SARS-CoV-2. These tests, which are primarily enzyme-linked  
68 immunosorbent assay (ELISA)-based, provide a convenient way to identify individuals  
69 previously infected with SARS-CoV-2. However, it is well-known that only a small subset of

70 virus-specific antibodies are capable of neutralizing virus infectivity, and thereby protecting  
71 against future viral infection and disease (12). Importantly, the rapid serological assays for which  
72 EUA approvals have been granted are not able to discriminate between neutralizing and non-  
73 neutralizing antibodies. Available evidence also suggests that post-vaccination and post-infection  
74 neutralizing antibody titers do not correlate strongly with total antibody titers (10,13–16), and it  
75 is unknown whether neutralizing antibody titers decay over time more rapidly than non-  
76 neutralizing antibodies. Thus, for reliable assessment of the level of protection against SARS-  
77 CoV-2 infection in vaccinated or previously infected individuals, neutralizing antibody assays  
78 are preferred.

79 The gold standard assay for the quantitation of virus neutralizing antibodies is the plaque-  
80 reduction neutralization test (PRNT). While providing a reasonable measure of the blood  
81 concentration of antibodies capable of neutralizing the SARS-CoV-2 virus, PRNT is labor  
82 intensive and requires use of a clinical virus isolate, such that the test can only be performed  
83 under biosafety level 3 containment. Safer alternative neutralization assays have been developed  
84 using non-replicating lentiviral vectors (10,14,17,18) or vesicular stomatitis viruses (VSVs)(19)  
85 pseudotyped with the SARS-CoV-2 spike glycoprotein. However, due to technical factors  
86 impacting the manufacture of these pseudotyped viruses, they are generally produced in small  
87 batches of variable titer, which significantly limits the scalability of these assays. The use of  
88 fully replication competent VSVs expressing the SARS-CoV-2 spike protein provides an  
89 attractive alternative for the development of neutralizing assays (20–22), as they can be  
90 propagated extensively to generate much larger reagent stocks. Moreover, because the natural  
91 VSV glycoprotein (G) is replaced with the SARS-CoV-2 spike protein, these recombinant  
92 viruses mimic SARS-CoV-2 entry, which is initiated by binding of the spike protein to its

93 receptor angiotensin-converting enzyme 2 (ACE2) on the cell surface (23–25). Once bound to  
94 ACE2 via its receptor binding domain (RBD), the spike protein is proteolytically cleaved by the  
95 cell surface transmembrane serine protease TMPRSS2 or by endosomal cysteine proteases  
96 cathepsin B/L, providing a critical trigger for subsequent membrane fusion and virus entry into  
97 the cell (23,26). Studies have mapped the targets of SARS-CoV-2-neutralizing antibodies to  
98 diverse epitopes within the spike protein, and antibodies that block ACE2 receptor binding, spike  
99 protein cleavage, or subsequent conformational rearrangements of the spike protein that lead to  
100 membrane fusion are all strongly neutralizing (27–31).

101 Here, we describe the development, optimization, and validation of IMMUNO-COV™ v2.0,  
102 a fully scalable neutralization assay that uses a replication competent G cistron-deleted  
103 recombinant VSV encoding both the SARS-CoV-2 spike protein and firefly luciferase (Fluc)  
104 (Fig. 1). Over 23,000 vials of this virus were prepared and cryopreserved from a single large-  
105 production run, providing sufficient material to assay more than 5 million serum or plasma  
106 samples. Anti-SARS-CoV-2-neutralizing antibody titers determined using IMMUNO-COV™  
107 v2.0 demonstrated strong linear correlation with titers obtained using the classical PRNT under  
108 BSL-3. IMMUNO-COV™ v2.0 assay performance has remained robust and accurate for at least  
109 three months, during which time we have conducted extensive validation testing and subsequent  
110 verification studies. In keeping with the observations of other groups (7,8,16,28,32), higher titers  
111 of neutralizing antibodies were observed in subjects recovering from more severe SARS-CoV-2  
112 infections, though strong responses were also seen in several subjects who had only mild disease  
113 symptoms. Importantly, a substantial decline in neutralizing antibody levels was observed in  
114 most COVID-19 convalescent subjects who were tested repeatedly over a six-month period,  
115 regardless of the initial antibody titer. Taken together, our results underscore the importance of

- 116 monitoring neutralizing antibody titers of over time, and demonstrate how IMMUNO-COV™
- 117 v2.0 can be used to accurately quantify these responses at scale.

118

## Results

119       ***Generation of VSV-SARS2-Fluc.*** Our previously published SARS-CoV-2 neutralization  
120 assay relied upon virus-induced fusion of two dual split protein (DSP) reporter cell lines to  
121 generate a luciferase signal (21). To further improve assay throughput and eliminate the need for  
122 two cell lines we generated a recombinant VSV (VSV-SARS2-Fluc) encoding SARS-CoV-2  
123 spike- $\Delta$ 19CT (S- $\Delta$ 19CT) in place of VSV-G, and firefly luciferase (Fluc) as an additional  
124 transcriptional unit located between the S- $\Delta$ 19CT and VSV-L genes (Fig. 2A). Cells infected  
125 with VSV-SARS2-Fluc express the virus-encoded luciferase, which is used to measure the level  
126 of virus infection. Incorporation of SARS-CoV-2 spike protein into VSV-SARS2-Fluc virions  
127 was confirmed by immunoblot (Fig. 2B). VSV-SARS2-Fluc infection and replication were also  
128 dependent on cellular ACE2 expression. Robust VSV-SARS2-Fluc replication and virus-induced  
129 cell death were observed in Vero-ACE2 cells, which overexpress the SARS-CoV-2 receptor  
130 ACE2 (Fig. 2C and D), but not in hamster BHK-21 cells (Fig. 2C and E), which do not express  
131 human ACE2. The control virus VSV-Fluc, which encodes VSV-G, but not S- $\Delta$ 19CT, efficiently  
132 infected and replicated in Vero-ACE2 and BHK-21 cells. Cellular luciferase activity specifically  
133 correlated to replication of the Fluc-expressing viruses (Fig. 2F and G), with loss of luciferase  
134 signal at later timepoints coinciding with the death of infected cultures. Together, these data  
135 confirmed functional VSV-G replacement with S- $\Delta$ 19CT and efficient Fluc expression from the  
136 VSV-SARS2-Fluc virus.

137       ***Vero-ACE2 cells are an optimal cell substrate for detecting virus neutralization.*** VSV-  
138 SARS2-Fluc infects Vero cells via endogenously expressed ACE2 receptors (21). We  
139 hypothesized that ACE2 overexpression could enhance Vero cell susceptibility to VSV-SARS2-  
140 Fluc and thereby improve assay sensitivity. To this end, we tested Vero-ACE2 cells, which

141 stably overexpress human ACE2 as confirmed by flow cytometry (Fig. 2H and I), in the assay.  
142 While Vero and Vero-ACE2 cells naturally express relatively high levels of TMPRSS2 (Fig. 2J  
143 and K), we also generated a stable cell line overexpressing both ACE2 and TMPRSS2 to  
144 elucidate the effect of TMPRSS2 on assay performance. VSV-SARS2-Fluc infection induced  
145 higher luciferase expression in Vero-ACE2 cells compared to Vero cells (Fig. 3A). Luciferase  
146 expression was not further enhanced by overexpression of TMPRSS2, and notably, VSV-  
147 SARS2-Fluc neutralization by the well-characterized neutralizing anti-SARS-CoV-2 spike  
148 monoclonal antibody mAb10914 was less apparent on Vero-ACE2/TMPRSS2 cells compared to  
149 Vero-ACE2 cells (Fig. 3A). Since Vero-ACE2 cells provided for more sensitive detection of  
150 viral neutralization, these cells were selected as the cell substrate for assay development.

151 We also examined the effect of Vero-ACE2 cell seeding density on assay performance.  
152 Higher luciferase activity was detected when cell density was increased from 5,000 to 10,000  
153 cells/well (96 well plate; Fig. 3B), but further increasing the cell density to 20,000 cells/well led  
154 to only a modest additional incremental increase in luciferase signal. Moreover, the higher cell  
155 density of 20,000 cells/well was associated with a less effective neutralization of luciferase  
156 signal when the virus was exposed to the neutralizing antibody mAb10914. We concluded that  
157 10,000 cells/well was the optimal seeding density for detection of virus neutralization.

158 To demonstrate the detection of neutralizing antibodies in patient samples, we used serum  
159 samples confirmed as seronegative or seropositive by the commercial EUROIMMUN Anti-  
160 SARS-CoV-2 ELISA (IgG), which detects anti-SARS-CoV-2 spike antibodies. Serum samples  
161 were incubated with VSV-SARS2-Fluc for 30 minutes at room temperature then added to culture  
162 wells containing pre-plated Vero-ACE2 cells. All five of the seropositive samples substantially  
163 inhibited virus infection, resulting in suppression of luciferase activity (Fig. 3C). No reduction in

164 luciferase activity was observed when the VSV-SARS2-Fluc virus was pre-incubated with  
165 seronegative samples, confirming that neutralizing antibodies were detected only in seropositive  
166 donor samples.

167 ***Consistency of different VSV-SARS2-Fluc production lots.*** To determine the optimal  
168 quantity of virus to add to each assay well, we tested the capacity of mAb10914 and seropositive  
169 plasma to neutralize increasing amounts of VSV-SARS2-Fluc. Highly neutralizing seropositive  
170 plasma and mAb10914 at a concentration of 2  $\mu\text{g}/\text{mL}$  inhibited infectivity by at least 90%,  
171 independent of the amount of virus added to the well (Fig. 4A). In contrast, mAb10914 at a  
172 concentration of 0.2  $\mu\text{g}/\text{mL}$  noticeably blocked infectivity in this assay only when less than 900  
173 plaque forming units (pfu) of virus were added to each well. Based on this experiment, the  
174 optimal quantity of VSV-SARS2-Fluc virus to be added to each well to ensure sensitive  
175 detection of low-levels of neutralizing antibodies is between 200 and 400 pfu. Consistency of  
176 virus lots was confirmed by comparing mAb10914 inhibition of two independent lots of VSV-  
177 SARS2-Fluc (produced at different times and representing subsequent virus passages).  
178 Luciferase activity over a range of concentrations of mAb10914 was nearly indistinguishable  
179 between the two different virus lots (Fig. 4B). Comparing the mAb10914 inhibition curve with  
180 200, 300, and 400 pfu of virus per well, the linear range was slightly wider when 300 pfu/well of  
181 VSV-SARS2-Fluc was used. Therefore, we used 300 pfu for all future assay runs. We also tested  
182 the stability of the thawed VSV-SARS2-Fluc virus when stored on ice or at room temperature  
183 prior to being used in the assay. No significant reduction in virus infectivity or neutralization  
184 occurred following an 8-hour incubation on ice (Fig. 4C). Likewise, the virus was stable for up  
185 to an hour at room-temperature, with only a modest titer decrease noted after two hours (Fig.  
186 4D).

187        ***Heat-inactivation of serum samples is not necessary for assay compatibility.*** In cellular  
188 assays, heat-inactivation of plasma and serum samples is often necessary to limit matrix  
189 interference that can affect cell or virus viability. To determine whether heat-inactivation was  
190 required for IMMUNO-COV<sup>TM</sup> v2.0, twenty matched serum and plasma samples were thawed  
191 and aliquoted, with one aliquot kept on ice, while the other aliquot was heat-inactivated at 56°C  
192 for 30 minutes. Both aliquots were then tested in the assay. Overall, heat-inactivation had little  
193 effect on neutralizing activity. All seronegative samples remained negative and all seropositive  
194 samples remained positive in the assay, regardless of whether the samples had been heat-  
195 inactivated (Fig. 5A and 5B). Importantly, heat-inactivated samples did not exhibit diminished  
196 virus neutralizing capacity, suggesting that complement proteins do not enhance the  
197 neutralization of VSV-SARS2-Fluc in this assay format. For plasma samples, heat-inactivation  
198 and subsequent clarification prevented thermal coagulation and sample loss during the assay,  
199 thereby improving assay performance. We therefore continued to use heat-inactivation for all  
200 subsequent assays with plasma samples, while using non-heat-inactivated serum samples.

201        ***Serum and plasma demonstrate low matrix interference.*** In our original cell fusion-based  
202 IMMUNO-COV<sup>TM</sup> assay we observed significant matrix interference at high concentrations of  
203 serum and plasma (21). To determine whether IMMUNO-COV<sup>TM</sup> v2.0, which provides a more  
204 direct measure of virus infection, is similarly hampered by matrix interference, we ran numerous  
205 seronegative samples in the assay at 2-fold serial dilutions ranging from 1:20 through 1:640.  
206 Minimal matrix interference was observed with serum, sodium-heparin plasma, ACD plasma,  
207 and K2-EDTA plasma (Fig. 5C, D, E, and F). In fact, higher concentrations of plasma appeared  
208 to have a stabilizing effect on the virus relative to cell culture medium alone and were associated  
209 with higher levels of luciferase activity at assay readout. Likewise, serum appeared to increase

210 virus stability relative to medium alone, though some matrix interference was observed at the  
211 1:20 dilution. Thus, the IMMUNO-COV™ v2.0 assay is compatible with testing at low sample  
212 dilutions, which may be of importance if higher detection sensitivities are desired.

213 ***Quantification of neutralizing antibody titers using a standard curve.*** To determine the titer  
214 of neutralizing antibodies in a test sample without the need for serial two-fold sample dilutions,  
215 we developed an assay format in which just one or two dilutions of a test sample are read against  
216 a standard calibration curve included on every assay plate. For the development of a calibration  
217 standard and assay controls, we used two well-characterized neutralizing anti-spike monoclonal  
218 antibodies, mAb10914 and mAb10922. Both antibodies neutralized VSV-SARS2-Fluc in a dose-  
219 dependent manner (Fig. 6A), whereas no virus inhibition was observed using isotype antibody at  
220 any of the concentrations tested. Based on these findings we established a six-point standard  
221 curve using two-fold dilutions of mAb10914 in tissue culture medium at concentrations ranging  
222 from 0.8 µg/mL to 0.025 µg/mL (Fig. 6B). To quantify the viral neutralizing titers of test  
223 samples, each antibody concentration in the standard curve was converted to a virus neutralizing  
224 titer (VNT) by multiplying the antibody concentration by 400. The correction factor of 400 was  
225 chosen as it produced VNT values that approximated PRNT50% values obtained for samples  
226 assayed at a 1:80 dilution (see below). The final standard curve range for the assay therefore  
227 gives a VNT readout of 10-320 for a sample assayed at a 1:80 dilution. In numerous tests (n=242  
228 assay runs), the 160, 80, 40, and 20 VNT standards fell within the linear range >99% of the time  
229 (Table 1). In most runs (87.6%), either the 320 or 10 VNT standard was also within the linear  
230 range. Thus, the standard curve effectively spanned the assay linear range. To quantitate  
231 antibody titers above 320 VNT, additional sample dilutions above 1:80 were employed in the  
232 assays described below.

233        ***Under standard conditions the assay limit of detection is 32 VNT.*** To determine the limit of  
234 detection (LOD) of the assay we first determined the assay limit of blank (LOB), representing  
235 the background signal from seronegative serum. To this end, we assayed seven known  
236 seronegative serum samples at a 1:80 dilution on 12 assay runs and calculated the luciferase  
237 signal as a percentage of the signal in media only controls. As observed previously (Fig. 5C),  
238 seronegative samples stabilized virus, and the LOB was a luciferase response of 124.5%  
239 compared to media alone. Seronegative serum samples were subsequently spiked with low  
240 concentrations of standard mAb10914 (0.01, 0.02, 0.04, 0.06, 0.08, and 0.1 µg/mL,  
241 corresponding to VNTs of 4, 8, 16, 24, 32, and 40) and assayed side-by-side with unspiked  
242 samples (Fig. 6C). Based on a total of 60 values obtained for each spike level, the lowest  
243 concentration of mAb10914 at which  $\geq 95\%$  of the luciferase response values were below the  
244 LOB was 0.08 µg/mL. This concentration corresponded to a VNT of 32, which was accepted as  
245 the LOD for the assay.

246        ***The assay exhibits high specificity and sensitivity.*** To evaluate the sensitivity and specificity  
247 of IMMUNO-COV™ v2.0 when used to discriminate between positive and negative results, we  
248 performed blinded testing of 176 serum samples that were categorized as either positive or  
249 negative for SARS-CoV-2-neutralizing antibodies based on the readouts from ELISA and gold  
250 standard PRNT. All samples that tested positive for SARS-CoV-2 spike binding antibodies by  
251 ELISA were subsequently analyzed by PRNT, with only those samples that were positive by  
252 PRNT considered positive for neutralizing antibodies. Samples that tested negative by ELISA  
253 but positive in the IMMUNO-COV™ v2.0 assay were also tested by PRNT to confirm the  
254 presence or absence of neutralizing antibodies. In these analyses, our assay demonstrated 100%  
255 specificity when compared to both PRNT50% and PRNT80% results, as all PRNT-negative

256 samples tested negative in IMMUNO-COV™ v2.0 (Table 2). Assay sensitivity was 93.7%  
257 relative to PRNT50% and 98.4% relative to PRNT80%. Moreover, 140 serum samples acquired  
258 prior to March 2020 (134 acquired from 2017-2019, 5 acquired in early 2020) from donors  
259 recovered from infection with endemic human coronaviruses HKU1 (n=35), NL63 (n=32), OC43  
260 (n=35), or 229E (n=35) were all negative for neutralizing antibodies when tested using the  
261 IMMUNO-COV™ v2.0 assay. Thus, the assay specifically detected neutralizing antibodies to  
262 SARS-CoV-2 and most likely does not cross react to the four common human coronaviruses.

263 We also assessed assay variability. Each of the blinded serum samples was assayed on five  
264 distinct runs performed by four different operators over a period of five days. Perfect consensus  
265 of positive and negative results between all five runs was observed for 174 (98.9%) of the  
266 samples. Antibody titers of positive samples were consistent between operators and assay runs,  
267 with titers across five different runs exhibiting 27.9% CV (n=59), which compared favorably to a  
268 CV of 65.1% for the PRNT (n=8 samples, two separate runs). Inter-assay precision was also  
269 evaluated based on the performance of the standard curve and assay controls. For this purpose,  
270 we included quality control (QC) high (0.154 µg/mL) and QC low (0.031 µg/mL) controls  
271 consisting of mAb10922 spiked into negative pooled sera on each assay plate. From 207 assay  
272 runs, QC high and QC low VNT readouts both demonstrated less than 30% inter-assay  
273 variability (Table 3 and Fig. 7). Intra-assay variability, which was assessed by running the same  
274 controls in 24 wells of the same plate, was below 20% for both controls (QC high = 8.6%, QC  
275 low = 19.1%). Collectively, these data demonstrate that the IMMUNO-COV™ v2.0 assay has  
276 acceptably low levels of intra- and inter-assay variability.

277 *Assay equivalence of serum and plasma samples.* While most of our assay validation studies  
278 were conducted using serum samples, we also performed matrix equivalency testing to confirm

279 assay compatibility with different plasma matrices. To this end, we acquired matched serum,  
280 sodium heparin plasma, ACD plasma, and K2/EDTA plasma samples from 26 of the 176  
281 subjects whose serum samples were used to evaluate assay specificity and sensitivity, and tested  
282 the matched samples side-by-side in the assay. The consensus results and VNT antibody titers of  
283 positive samples from five assay runs were compared for each matrix. The average percentage  
284 relative error for each matrix was within  $\pm 30\%$  for all plasma matrices (Table 4). Although all  
285 three plasma matrices demonstrated equivalency in this experiment, in other experiments (data  
286 not shown) the sodium heparin plasma samples did not exhibit dilutional linearity. Thus, only  
287 ACD plasma and K2/EDTA plasma are currently considered acceptable matrices for clinical  
288 testing.

289 ***IMMUNO-COV™ v2.0 VNT antibody titers correlate closely to PRNT50% titers.*** The BSL-  
290 3 PRNT with wild-type SARS-CoV-2 remains the gold standard for detection of neutralizing  
291 antibodies. Therefore, we compared the titers (VNT) measured using IMMUNO-COV™ v2.0  
292 with those determined by PRNT. A strong correlation (Pearson's  $R = 0.8870$ ,  $p < 0.0001$ ) was  
293 observed between VNTs and PRNT50% titers (Fig. 8). Therefore, neutralization of VSV-  
294 SARS2-Fluc in our assay closely mirrors the neutralization of SARS-CoV-2, and IMMUNO-  
295 COV™ v2.0 titers provide an accurate measure of an individual's level of neutralizing  
296 antibodies. Moreover, VNTs can be quickly compared to PRNT50% titers using a conversion  
297 table (Table 5), which we generated based on our data obtained using the two different assays.

298 ***Individuals with more severe disease symptoms tend to develop higher titers of neutralizing***  
299 ***antibodies.*** Increasing evidence indicates that disease severity influences the strength of the  
300 neutralizing antibody response (7,8,16,28,32). To examine whether individuals in our study with  
301 more severe disease developed higher titers of neutralizing antibodies, we correlated antibody

302 titers with self-reported disease symptoms from 46 previously infected donors who had tested  
303 positive for SARS-CoV-2-neutralizing antibodies. Samples used for this analysis were collected  
304 within the time window of two weeks to two months post confirmation of COVID-19 diagnosis.  
305 A wide range of neutralizing antibody titers was observed among these donors with significant  
306 overlap between the disease severity groupings (Fig. 9). Mean neutralizing antibody titers  
307 increased with increasing disease severity, though differences were not statistically significant.  
308 Our data, therefore, support previous findings that strong neutralizing antibody responses are  
309 more likely in individuals who have recovered from severe disease, but wide variation in  
310 neutralizing titers occur within all disease severity groupings.

311 *SARS-CoV-2-neutralizing antibody titers fall steadily after recovery from infection.* To  
312 provide long-term protection from COVID-19, neutralizing antibodies must persist at sufficiently  
313 high levels to block infection or mitigate pathogenesis. To examine the durability of SARS-CoV-  
314 2-neutralizing antibodies after recovery from natural infection, we determined the change in  
315 neutralizing antibody titers from 13 subjects between April and October 2020. In April, all 13 of  
316 these subjects had been diagnosed with COVID-19 within the previous two months and had  
317 measurable levels of SARS-CoV-2-neutralizing antibodies. Samples collected in April were  
318 stored at  $\leq -65^{\circ}\text{C}$  and assayed side-by-side with new samples collected in October from the same  
319 subjects. A two- to five-fold drop in neutralizing antibody titers was observed in all but one  
320 subject (Fig. 10A and Table 6). The outlier showed a 3-fold increase, suggesting possible  
321 asymptomatic re-exposure to the virus. In three subjects, the VNT from October dropped below  
322 the limit of detection in serum, though neutralizing antibodies could still be detected at very low  
323 levels in ACD-plasma from two of these subjects. Together, these data indicate that SARS-CoV-  
324 2 neutralizing antibody titers fall quite rapidly over time following natural infection. Importantly,

325 while the PRNT confirmed the substantial decrement in SARS-CoV-2-neutralizing antibody  
326 titers over six months (Fig. 10B), a similar trend was not observed using a “neutralization” assay  
327 that measures binding of the spike RBD to immobilized ACE2 receptor (Fig. 10C and Table 6).  
328 When samples were tested using this SARS-CoV-2-spike RBD binding assay, antibody levels in  
329 several subjects were similar in April and October. This finding highlights the importance of  
330 quantifying neutralizing antibodies by inhibition of live virus rather than relying on a surrogate  
331 receptor binding assay.

332

## **DISCUSSION**

333 With vaccine roll-out ongoing and critical questions still unanswered regarding the durability  
334 of protective immune responses, the need for an accurate, scalable test that can quantitatively  
335 measure SARS-CoV-2-neutralizing antibodies remains a priority. Only a small subset of  
336 antibodies capable of binding to the spike glycoprotein have neutralizing activity and are most  
337 likely to afford protection against SARS-CoV-2 infection (16,27,29,33). Commercially available  
338 monoclonal antibodies proven to be of benefit for the treatment of COVID-19 were selected  
339 based on their potent virus neutralizing activity (34–38). Yet, most serological tests currently in  
340 use detect total spike-binding antibodies but do not measure the capacity of these antibodies to  
341 neutralize virus infectivity. The traditional assay for detection and quantification of neutralizing  
342 antibodies, the PRNT, is low-throughput and for SARS-CoV-2 must be performed under high  
343 biocontainment (BSL-3), making it impractical for widespread use. Here, we describe the  
344 development and clinical validation of a novel assay, IMMUNO-COV™ v2.0, which is now  
345 available as a scalable laboratory developed test for quantitatively measuring SARS-CoV-2-  
346 neutralizing antibody titers. Our data show that IMMUNO-COV™ v2.0 can be used for accurate  
347 tracking of neutralizing antibody titers over time in individuals following natural infection or  
348 vaccination (Fig. 10). Such information will be needed to better define what constitutes a  
349 protective immune response, and what is the durability of the protective immune response  
350 following natural infection or vaccination. Answers to these questions will be important to better  
351 inform vaccine dosing schedules and other public health initiatives aimed at controlling the  
352 pandemic.

353 The IMMUNO-COV™ v2.0 assay measures the concentration of antibodies in serum or  
354 plasma that can neutralize the infectivity of the VSV-SARS2-Fluc virus in Vero-ACE2 cells, as

355 detected by a reduction in luciferase activity compared to cells that have been infected in the  
356 absence of neutralizing antibodies (Fig. 1). Importantly, results from IMMUNO-COV™ v2.0  
357 correlate closely with PRNT50% titers determined using a clinical isolate of SARS-CoV-2 (Fig.  
358 8), indicating that neutralization of VSV-SARS2-Fluc accurately mirrors SARS-CoV-2  
359 neutralization. Other groups have likewise observed strong correlation between the readouts of  
360 virus neutralization assays using VSV and lentiviral pseudotypes displaying the SARS-CoV-2  
361 spike glycoprotein and readouts of classical PRNT conducted under BSL-3 using clinical isolates  
362 of SARS-CoV-2 (18,22,39). Given the strong correlations between titers determined using  
363 IMMUNO-COV™ v2.0 and those determined using classical PRNT50% and PRNT80% assays,  
364 we generated a conversion table that facilitates the rapid conversion of IMMUNO-COV™ v2.0  
365 titers to corresponding PRNT50% titers (Table 5). Moreover, the VNT scale for IMMUNO-  
366 COV™ v2.0 was designed to yield numerical values roughly equivalent to the PRNT50% titers  
367 obtained for a given sample.

368 The currently available spectrum of tests for determining titers of SARS-CoV-2-neutralizing  
369 antibodies are based on clinical isolates of SARS-CoV-2 (PRNT) (40–42), replicating surrogate  
370 viruses (typically VSV-derived) (20–22), non-replicating spike protein pseudotyped viruses  
371 (primarily using VSV or lentiviruses) (10,14,17–19), or entirely nonviral platforms (RBD-ACE2  
372 binding assays) (43,44). Binding assays using spike receptor binding domain (RBD) are  
373 attractive due to the speed at which results can be obtained. However, they measure only that  
374 subset of neutralizing antibodies capable of blocking the binding of the SARS-CoV-2 spike  
375 protein RBD to its immobilized ACE2 receptor. They do not functionally measure virus  
376 neutralization, and since only a portion of SARS-CoV-2-neutralizing antibodies binds to the  
377 RBD (27,29), the relevance of these assays relative to those that directly measure the inhibition

378 of virus infection remains an open question. In relation to this important question, we observed a  
379 strong correlation between IMMUNO-COV<sup>TM</sup> v2.0 and PRNT50% titers in samples acquired at  
380 different times following SARS-CoV-2 infection. In contrast, we observed a much less robust  
381 correlation between PRNT50% titers and the c-Pass SARS-CoV-2 surrogate virus neutralization  
382 test kit, which is a spike RBD binding assay (Fig. 10).

383 In addition to comparing our assay to the gold standard PRNT assay, we performed full  
384 clinical validation of IMMUNO-COV<sup>TM</sup> v2.0, which included evaluating the parameters of  
385 linearity, assay dynamic range, sensitivity, determination of the limit of blank (LOB) and limit of  
386 detection (LOD), dilutional linearity and parallelism, precision, clinical agreement, matrix  
387 equivalence, clinical specificity and sensitivity, and assay robustness. IMMUNO-COV<sup>TM</sup> v2.0  
388 exhibited excellent clinical agreement with 100% assay specificity (Table 2). We also tested  
389 samples obtained predominately before 2019 from individuals recovered from infection with one  
390 of the four common human coronaviruses (HKU1, NL63, OC43, or 229E). All these samples  
391 tested negative for neutralizing antibodies, suggesting that IMMUNO-COV<sup>TM</sup> v2.0 is specific to  
392 SARS-CoV-2-neutralizing antibodies and most likely will not detect neutralizing antibodies  
393 directed against other human coronaviruses.

394 As has been reported by others (7,8,16,28,32), we observed that donors recovering from  
395 more severe COVID-19 disease generally developed higher-titer neutralizing antibody responses  
396 (Fig. 9). However, several individuals with only mild COVID-19 symptoms developed strong  
397 neutralizing antibody responses, and two individuals with severe disease developed relatively  
398 weak neutralizing antibody responses. Thus, SARS-CoV-2-neutralizing antibody titers cannot be  
399 accurately predicted based on the severity of the disease manifestations that an individual  
400 experiences, highlighting the importance of neutralizing antibody testing to determine anti-

401 SARS-CoV-2 immune status. Irrespective of the initial magnitude of the neutralizing antibody  
402 response, repeat IMMUNO-COV™ v2.0 testing demonstrated a relatively steep decline in  
403 SARS-CoV-2-neutralizing antibody titers over six months (Fig. 10). This finding is in keeping  
404 with those of other investigators (7–11), and highlights the importance of tracking neutralizing  
405 antibodies over time. It should be noted that some other studies suggest that SARS-CoV-2-  
406 neutralizing antibody titers are relatively stable (45,46). More research is needed to better  
407 understand the durability of neutralizing antibody responses to SARS-CoV-2 and their  
408 relationship to cell-mediated responses. Further investigation is also needed to determine  
409 whether vaccination provides immunity against SARS-CoV-2 viral variants, and we are  
410 conducting ongoing studies to confirm that IMMUNO-COV™ v2.0 can detect immunity against  
411 SARS-CoV-2 variants.

412 It is not currently known what minimum titer of SARS-CoV-2-neutralizing antibodies is  
413 necessary to assure protection against future infection. Likely there will be considerable variation  
414 between individuals because of the multiple additional factors impacting susceptibility to  
415 infection, including age, sex, race, ethnicity, and various comorbid conditions. Nevertheless, it is  
416 widely accepted that higher levels of neutralizing antibodies afford a higher degree of protection  
417 from future infection. Large, coordinated studies following SARS-CoV-2-neutralizing antibody  
418 titers in various cohorts of vaccinated and previously infected individuals will be needed to  
419 understand immune correlates of protection, the durability of the protective response, and the  
420 appropriate frequency for administration of booster doses of the approved SARS-CoV-2  
421 vaccines. With the advent of IMMUNO-COV™ v2.0, a fully validated, high throughput  
422 laboratory developed test that accurately and robustly determines neutralizing antibody titers, we  
423 can now move forward with these much-needed population studies. We have generated and

424 cryopreserved sufficient VSV-SARS2-Fluc virus to perform over 5 million assays, and the assay  
425 is accurate and reproducible even between different virus lots (Fig. 4). Moreover, during  
426 validation testing, the IMMUNO-COV<sup>TM</sup> v2.0 assay exhibited favorable precision compared to  
427 the PRNT, with acceptable levels of intra- and inter-assay variability (Table 3) and low run-to-  
428 run variability in quantitative VNT readouts. Therefore, we believe that IMMUNO-COV<sup>TM</sup> v2.0  
429 will provide a useful and lasting standardized assay that can be used to normalize and harmonize  
430 neutralizing antibody titers for consistent monitoring of neutralizing antibody levels over time  
431 and in large study populations.

432

## **MATERIALS AND METHODS**

433 *Cells:* African green monkey Vero cells (ATCC® CCL-81™), Vero- $\alpha$ His (47), and baby  
434 hamster kidney BHK-21 cells (ATCC® CCL-10™) were maintained in high-glucose DMEM  
435 supplemented with 5% fetal bovine serum and 1X penicillin/streptomycin (complete media) at  
436 37°C/5% CO<sub>2</sub>. Vero-ACE2-Puro (Vero-ACE2) cells were generated by transducing Vero cells  
437 with lentiviral vector LV-SFFV-ACE2-Puro, encoding the human ACE2 cDNA (GenBank  
438 BC039902) under control of the spleen focus forming virus (SFFV) promoter and linked to the  
439 puromycin resistance gene via a P2A cleavage peptide. Vero-ACE2-Puro/TMPRSS2-Puro  
440 (Vero-ACE2/TMPRSS2) cells were generated by transducing Vero-ACE2-Puro cells with  
441 lentiviral vector SFFV-TMPRSS2-Puro encoding human TMPRSS2 cDNA (GenBank:  
442 BC051839) under control of the SFFV promoter and linked to the puromycin resistance gene via  
443 a P2A cleavage peptide. Vectors used for stable-cell generation were verified by whole plasmid  
444 sequencing performed by MGH CCIB DNA Core (Cambridge, MA). Transduced cells were  
445 selected using 10  $\mu$ g/mL puromycin. Following selection, Vero-ACE2 cells were maintained in  
446 complete media supplemented with 5  $\mu$ g/mL puromycin. Puromycin was excluded when cells  
447 were seeded for assays.

448 *Generation of VSV-SARS2-Fluc:* Full-length Luc2 (Fluc) was PCR-amplified from pLV-  
449 SFFV-Luc2-P2A-Puro (Imanis #DNA1034) with a 5' NheI and 3' AscI restriction site. To  
450 generate the viral genome, the amplified PCR product was cloned into pVSV-SARS-CoV-2-S-  
451  $\Delta$ 19CT (21) between the S $\Delta$ 19CT and L genes (Figure 2A) using the NheI and AscI restriction  
452 sites. Plasmid was sequence verified and used for infectious virus rescue on BHK-21 cells as  
453 previously described (48). VSV-G was co-transfected into the BHK-21 cells to facilitate rescue  
454 but was not present in subsequent passages of the virus. For initial amplification, the virus was

455 propagated in Vero- $\alpha$ His cells by inoculating 80% confluent monolayers in 10-cm plates with 1  
456 mL of virus. Virus was harvested 48 h after inoculation, aliquoted, and stored at  $\leq -65^{\circ}\text{C}$  until  
457 use. For further amplifications and generation of large-scale stocks, the virus was propagated in  
458 Vero-ACE2 cells by inoculating 90% confluent monolayers at an MOI of 0.02 or 0.03 plaque  
459 forming units per cell. Virus was harvested after 48 h, aliquoted, and stored at  $\leq -65^{\circ}\text{C}$  until use.  
460 Aliquots were used to determine viral titers by plaque assay on Vero- $\alpha$ His cells.

461 *Replication Curves:* Vero-ACE2 or BHK-21 monolayers in 10-cm plates were inoculated in  
462 duplicate with OptiMEM alone (mock), VSV-Fluc (MOI=0.01), or VSV-SARS2-Fluc  
463 (MOI=0.01). After 2 h at  $37^{\circ}\text{C}/5\% \text{CO}_2$ , complete media was added to a total volume of 6 mL/  
464 plate. At 2, 12, 24, 36, and 48 h, 0.25 mL aliquots of culture supernatant were removed from  
465 plates and replaced with 0.25 mL of fresh media. Aliquots were stored at  $\leq -65^{\circ}\text{C}$  immediately  
466 after collection until the time of titering. To determine viral titers, aliquots were thawed and  
467 assayed by plaque assay on Vero- $\alpha$ His cells. Throughout the infection time course, cell photos  
468 were taken from the 10-cm plates at a 100x magnification using an inverted microscope.

469 *Reagents:* D-luciferin potassium salt (Gold Biotechnology #LUCK-1G) was diluted in DPBS  
470 to generate 15 mg/mL stocks. For initial studies, 20  $\mu\text{L}$ /well of stocks were used for assays. For  
471 later studies (starting with validation studies), stocks were diluted 1:10 in DPBS and 50  $\mu\text{L}$ /well  
472 were used for assays. mAb10914 and mAb10922 are human  $\alpha$ -SARS-CoV-2 spike neutralizing  
473 monoclonal antibodies. mAb10914 was prepared and scaled up using methods previously  
474 described by Regeneron Pharmaceuticals, Inc. (35), and mAb10922 was purchased from  
475 GenScript (#U314YFG090\_1).

476 *Luciferase Assay Time Course:* Vero-ACE2 or BHK-21 cell monolayers in 96-well black-  
477 walled plates with clear bottoms were infected with VSV-Fluc or VSV-SARS2-Fluc at a

478 multiplicity of infection of 0.03 plaque forming units per cell. Media only wells were used as  
479 mock controls. For each condition, 24 wells were prepared to facilitate 8 time points done in  
480 triplicate. At 2, 12, 16, 20, 24, 28, 36, and 48 h after inoculation, d-luciferin was added to one set  
481 of triplicate wells and bioluminescence was immediately measured using a Tecan Infinite II  
482 instrument (100 ms integration, 100 ms settle time per well).

483 *Collection of Plasma and Sera Samples:* A clinical protocol to collect blood samples for  
484 assay validation was reviewed and approved by Western IRB on April 1, 2020 (study ID: VYR-  
485 COV-001). Samples were obtained with informed consent and the protocol was conducted under  
486 ICH-GCP and all applicable sections of the Code of Federal Regulations. Serum and plasma  
487 samples were collected in April 2020 from patients who had previously tested positive for  
488 SARS-CoV-2 infection by a PCR test, patients who had known exposure to individuals infected  
489 with SARS-CoV-2 and symptoms of COVID-19, and a cohort of patients with no known  
490 exposure to or symptoms of COVID-19 and presumed to be seronegative. Clinical information  
491 was self-reported. A total of 150 adult volunteers were enrolled and provided blood samples at  
492 BioTrial in Newark, New Jersey and Olmsted Medical Center in Rochester, Minnesota in April  
493 2020. A subset of 26 participants returned and volunteered a second blood sample 6 months later  
494 in October 2020.

495 Geisinger provided 140 frozen sera samples comprising the endemic human coronavirus  
496 panel. These samples were collected from subjects who had tested positive for the presence  
497 of coronavirus HKU1, coronavirus NL63, coronavirus OC43, coronavirus 229E using the  
498 Geisinger Respiratory Pathogen Panel PCR test (Geisinger Medical Labs) on average 282.5 days  
499 before the collection date (median: 129.3 days; range 1171.3 - 29.1 days).

500        *IMMUNO-COV<sup>TM</sup> v2.0 Neutralization Assays*: Except where noted during initial  
501 optimization experiments, Vero-ACE2 cells were seeded at  $1 \times 10^4$  cells/well in 96-well black-  
502 walled plates with clear bottoms 16-24 h before being used for neutralization assays. On the day  
503 of assay, test samples and controls were prepared and mixed with VSV-SARS2-Fluc in U-  
504 bottom suspension cell culture plates to a final volume of 240  $\mu$ L/well. Any indicated antibody  
505 concentrations or sample dilutions represent the antibody concentration or sample dilution  
506 following mix with virus. Except when noted otherwise, serum samples were thawed and used  
507 for assay without additional processing, while plasma samples were prepared by heat-  
508 inactivation for 30 min at 56°C, followed by clarification at  $12,000 \times g$  for 5 min and transfer of  
509 the liquid supernatant to fresh tubes. During initial optimization experiments, various  
510 concentrations of virus were tested, but for all subsequent assays, virus was used at 300 pfu/well  
511 (300 pfu/100  $\mu$ L in U-well mixtures). Virus, test samples, and controls were all diluted as  
512 appropriate in OptiMEM to generate final concentrations. For each plate, a standard curve  
513 consisting of 0.8, 0.4, 0.2, 0.1, 0.05, and 0.025  $\mu$ g/mL mAb10914 in OptiMEM, and controls NC  
514 (pooled negative matrix at 1:80), QC High (0.154  $\mu$ g/mL mAb1022 in pooled negative matrix at  
515 1:80), and QC Low (0.031  $\mu$ g/mL mAb10922 in pooled negative matrix at 1:80) were included.  
516 Virus mixes in U-well plates were incubated at room temperature for 30-45 min, and then 100  
517  $\mu$ L of mixes were overlaid onto the Vero-ACE2 monolayers in duplicate. Plates were returned to  
518 a 37°C/5% CO<sub>2</sub> incubator for 24-28 hours. D-luciferin was then manually added to wells using a  
519 multi-channel pipet, and luminescence was read immediately (30-90 seconds) after d-luciferin  
520 addition using a Tecan M Plex or Tecan Lume instrument (100 ms integration, 100 ms settle  
521 time per well).

522 *Determination of Virus Titers:* Virus neutralizing titers (VNTs) were determined based on a  
523 calibration curve. The calibration curve was run on each plate and consisted of mAb10914  
524 spiked into pooled SARS-CoV-2 seronegative sera at 0.8, 0.4, 0.2, 0.1, 0.05, and 0.025 µg/mL.  
525 From the calibration curve, the equivalent concentration of neutralizing antibody for a given  
526 luciferase signal was determined. To convert to VNT, the antibody equivalent concentration was  
527 multiplied by 400, a correction factor chosen to yield VNT values similar to PRNT50% values.

528 *Determinant of Limit of Blank (LOB) and Limit of Detection (LOD):* Seven known  
529 seronegative samples were analyzed at 1:80 dilution on 12 different assay runs, performed on  
530 three consecutive days, by six different analysts, using two separate virus lots. Luciferase signal  
531 relative to a media control was determined for each sample. The datasets were non-normal by  
532 Anderson-Darling and Shapiro-Wilk test, so the LOB was established using a non-parametric  
533 model with the 5<sup>th</sup> percentile value of relative luciferase response obtained for each dataset. From  
534 this analysis, the LOB was a response level of 124.5%. To determine the LOD, five seronegative  
535 samples (at 1:80 dilution) were spiked with low levels of calibrator material (mAb10914) at 0.01,  
536 0.02, 0.04, 0.06, 0.08, or 0.1 µg/mL and assayed on 12 different assay runs, performed on three  
537 consecutive days, by six different analysts, using two separate virus lots. Every run also included  
538 unspiked negative samples and media control. Datasets were evaluated for the titer that resulted  
539 in a response level below the corresponding LOB for each of the dilutions. From these analyses,  
540 the LOD was determined to be 32 VNT.

541 *Blinded Sample Testing:* Sera and plasma samples were randomized by independent  
542 operators prior to being given to analysts for testing. Samples were assayed in batches, with an  
543 unknown number of positive and negative samples in each batch. All samples were assayed at  
544 1:80, 1:160, 1:320, 1:640, 1:1280, and 1:2560 dilutions. For specificity and sensitivity studies,

545 each blinded sample was tested by four different analysts, on at least three different days, in a  
546 total of five separate assay runs, using two different virus lots. For comparison studies, samples  
547 were tested using the EUROIMMUN anti-SARS-CoV-2 ELISA (IgG) according to the  
548 manufacturer's directions.

549 *Assay Variability Assessment:* QC High (0.154 µg/mL), QC Low (0.031 µg/mL), and matrix  
550 blank (0 µg/mL) controls consisting of mAb10922 diluted in pooled negative serum (at 1:80)  
551 were used along with the standard curve to assess assay variability. For inter-assay variability  
552 studies, controls were tested in duplicate on a total of 207 assay runs performed by five different  
553 analysts across a span of five days using two different lots of virus. For intra-assay variability  
554 studies, each control was assayed in 24 wells in the same assay run performed by the same  
555 analyst.

556 *Matrix Equivalency Assessment:* Matched serum, sodium heparin plasma, ACD plasma, and  
557 K2/EDTA plasma samples were obtained (see Collection of plasma and sera samples). Samples  
558 were blinded and assayed as described for blinded sample testing, using appropriate pooled  
559 negative matrix controls.

560 *PRNT:* Serum samples were heat-inactivated for 30 min at 56°C and serially 2-fold diluted in  
561 Dulbecco's minimal essential medium supplemented with 2% heat-inactivated fetal bovine  
562 serum. SARS-CoV-2 (USA-WA1/2020) (49) was diluted to approximately 200 PFU/mL and  
563 mixed with an equal volume of diluted serum (final dilutions of serum with virus were 1:20,  
564 1:40, 1:80, 1:160, 1:320, 1:640, 1:1280, 1:2560, 1:5120, 1:10240, 1:20480, 1:40960). Virus  
565 mixed with an equal volume of medium alone was used as a control. After a 1 h incubation at  
566 37°C, 250 µL of virus/serum or virus/media mixes were used to inoculate Vero-E6 monolayers  
567 in 6-well plates. Absorption proceeded for 1 h at 37°C with occasional rocking, before

568 monolayers were overlaid with 4 mL of 1.6% low-melting agarose in Minimal Essential Media  
569 supplemented with 4% fetal bovine serum and antibiotics. Plates were incubated at 37°C for two  
570 days when plaques appeared, then fixed with 10% formaldehyde, and stained with 2 mL of  
571 0.05% neutral red, followed by incubation for 6 h at 37°C. Plaques were counted and the  
572 PRNT50% and PRNT80% titers were determined as the lowest dilution at which the number of  
573 plaques was reduced by 50% or 80%, respectively, compared to the virus/medium control.  
574 Plaque counts greater than 30 were too numerous to count and were considered as equivalent to  
575 the virus/media control.

576 *sVNT Binding Assay:* Serum samples were tested using the SARS-CoV-2 Surrogate Virus  
577 Neutralization Test (sVNT) Kit (GenScript #L00847) according to the manufacturer's directions.

578 *Flow Cytometry:* Vero- $\alpha$ His (Vero) or Vero-ACE2 cells were dislodged using Versene,  
579 counted, and transferred to microcentrifuge tubes ( $5 \times 10^5$  cells/tube was used for ACE2 staining  
580 and  $1.5 \times 10^6$  cells/tube was used for TMPRSS2 staining). For ACE2 staining, cells were pelleted  
581 and resuspended in 100  $\mu$ L FACS buffer (2% FBS in DPBS) containing 0.2  $\mu$ g goat- $\alpha$ -human  
582 ACE2 (R&D Systems #AF933). After 30 min on ice, cells were rinsed with 1 mL FACS buffer  
583 and resuspended in 100  $\mu$ L FACS buffer containing 5  $\mu$ L donkey- $\alpha$ -goat IgG-PE secondary  
584 antibody. After 30 min on ice, cells were rinsed with 1 mL FACS buffer and fixed with 1%  
585 paraformaldehyde for 15 min on ice. Cells were washed twice with FACS buffer, resuspended in  
586 500  $\mu$ L FACS buffer and analyzed on a CYTOFLEX flow cytometer (Beckman Coulter). For  
587 TMPRSS2 staining cells were resuspended in 1 mL ice-cold 70% ethanol in DPBS and incubated  
588 on ice for 10 min. Cells were centrifuged, washed once with 1 mL FACS buffer, and  
589 resuspended in 100  $\mu$ L of a 0.5% saponin solution containing 4  $\mu$ g rabbit  $\alpha$ -TMPRSS2  
590 (Invitrogen #PA5-14264). After 30 min on ice, samples were washed twice with 1 mL FACS

591 buffer and resuspended in 100  $\mu$ L of a 0.5% saponin solution containing 2  $\mu$ L goat  $\alpha$ -rabbit IgG-  
592 AF647 secondary antibody. After 30 min on ice, cells were washed twice with FACS buffer and  
593 fixed with 1% paraformaldehyde for 15 min on ice. Cells were washed twice with FACS buffer,  
594 resuspended in 500  $\mu$ L FACS buffer and analyzed on a CYTOFLEX flow cytometer (Beckman  
595 Coulter). For both ACE2 and TMPRSS2 staining, positive staining was compared against a  
596 control sample stained with secondary antibody only.

597 *Immunoblot:* Viruses were concentrated by high-speed centrifugation, and  $5 \times 10^5$  pfu (VSV-  
598 SARS2-Fluc) or  $5 \times 10^5$  TCID<sub>50</sub> units (VSV-GFP) were diluted in LDS sample buffer  
599 (Invitrogen #B0007) and reducing agent (Invitrogen #B0009) according to the manufacturer's  
600 directions. Cell lysates from HEK-293T cells stably expressing SARS-CoV-2 spike protein were  
601 also prepared as controls. All samples were incubated at 70°C for 10 min and 40  $\mu$ L of each  
602 sample was run in duplicate on 4-12% Bis-Tris gels (Invitrogen #NW04125Box) along with  
603 precision plus protein dual color standard (Bio-Rad #161-0374). Proteins were transferred to  
604 nitrocellulose membranes using a Power Blotter XL. Membranes were blocked in 5% non-fat dry  
605 milk in TBST, washed three times with TBST, and incubated for 1 h at room temperature with  
606 primary antibody mouse  $\alpha$ -SARS-CoV-2 Spike (1:1000, GeneTex #GTX632604) or mouse  
607 monoclonal  $\alpha$ -VSV-G clone 8G5F11 (1:10,000, Absolute Antibody #Ab01401-2.3). Membranes  
608 were washed three times with TBST and incubated for 1 h at room temperature with secondary  
609 antibody goat  $\alpha$ -mouse IgG-HRP (Prometheus #20-304) at 1:20,000. Membranes were washed  
610 three times with TBST, and protein bands were developed for 2 min at room temperature using  
611 ProSignal® Dura ECL Reagent (Prometheus #20-301). Protein bands were imaged using a  
612 BioRad ChemiDoc Imaging System.

613        *Statistical Analyses:* Descriptive statistics, comparisons, and regression analyses were  
614 performed in Graph Pad Prism, v9.0.0 (San Diego, CA). Tests for normality of variance were  
615 conducted, and whenever possible parametric comparisons were used. For non-normal datasets,  
616 non-parametric approaches were used. A four-parameter non-linear regression was used for the  
617 calibration curve of the virus neutralizing units within the assay. For correlation analyses,  
618 Spearman’s correlation analysis was conducted.

619

620

## **ACKNOWLEDGMENTS**

621 We would like to thank all the participants in our clinical trial, without whose willingness to  
622 donate blood we would not have been able to develop and validate this assay. We thank  
623 DiscovEHR Study with Geisinger Health System for the generous supply of serum samples from  
624 patients recovered from endemic coronavirus infection. We would also like to thank the entire  
625 Imanis Life Sciences, Vyriad, Regeneron, BioTrial, and OMC teams, and John Mills and Elitza  
626 Thiel at Mayo Clinic for helpful discussions, laboratory, and operational support. Natalie  
627 Thornburg provided the SARS-CoV-2 isolates and Kenneth and Jessica Plante provided SARS-  
628 CoV-2 stocks, cells, and protocols. Funding for this project was provided by Regeneron  
629 Pharmaceuticals, Inc. as part of an ongoing collaboration with Vyriad, Inc., and by NIH grant  
630 AI120942 to SCW.

631

## **AUTHOR CONTRIBUTIONS**

632 Designed and planned experiments: RV, TC, SR, CL

633 Performed experiments: RV, SR, CL, RN, L. Schnebeck, AR, KS, SW, GR

634 Analyzed data: RV, TC, SR, CL

635 Cloned and rescued virus: PL, CG, MH, SR

636 Generated critical reagents (cells, mAbs): JB, SR, A. Baum, CAK

637 Clinical trial implementation and test sample acquisition: A. Bexon, SN, BB, L. Suksanpaisan

638 Wrote the manuscript: RV, SJR

639 Contributed intellectually to assay development: RV, TC, SJR, L. Suksanpaisan, KWP, ST

640

641

## **CONFLICTS OF INTEREST**

642 Vyriad, Imanis Life Sciences, and Regeneron are collaborating in the commercial development

643 of this assay. Most coauthors of this manuscript are employees of at least one of the above

644 organizations as noted in the author affiliations. SJR and KWP are co-founding scientists,

645 officers, and stockholders both in Vyriad and Imanis Life Sciences.

646

647

## REFERENCES

- 648 1. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. 2021. Efficacy and  
649 Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med.* 384:403-16.
- 650 2. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. 2020. Safety  
651 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med.* 383:2603-15.
- 652 3. Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, et al. 2013.  
653 Accelerating Next Generation Vaccine Development for Global Disease Prevention.  
654 *Science.* 340:1232910.
- 655 4. Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. 2020. Development of an  
656 Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-  
657 2. *Cell.* 182:713-721.
- 658 5. Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, et al. 2020.  
659 DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science.* 369:806–11.
- 660 6. Plotkin SA. 2010. Correlates of protection induced by vaccination. *Clin Vaccine*  
661 *Immunol.* 17:1055–65.
- 662 7. Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan W hung, Chiu SS, et al. 2021.  
663 Neutralizing antibody titres in SARS-CoV-2 infections. *Nat Commun.* 12:1–7.
- 664 8. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, et al. 2020. Longitudinal  
665 observation and decline of neutralizing antibody responses in the three months following  
666 SARS-CoV-2 infection in humans. *Nat Microbiol.* 5:1598–607.
- 667 9. Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, et al. 2021.

- 668 Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory  
669 Syndrome Coronavirus 2 Infection. *J Infect Dis.* 223:197-205.
- 670 10. Brochet E, Demey B, Touzé A, Belouzard S, Dubuisson J, Schmit JL, et al. 2020. Anti-  
671 spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and  
672 Asymptomatic Individuals. *Front Microbiol.* 11:1–8.
- 673 11. Widge A, Roupheal NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, et al. 2021.  
674 Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. *N Engl J Med.*  
675 384:80–2.
- 676 12. Payne S. 2017. Immunity and Resistance to Viruses. *Viruses.* p. 61–71.
- 677 13. Nayak K, Gottimukkala K, Kumar S, Reddy ES, Edara VV, Kauffman R, et al. 2020.  
678 Characterization of neutralizing versus binding antibodies and memory B cells in COVID-  
679 19. *bioRxiv.* <https://doi.org/10.1101/2020.08.31.276675>.
- 680 14. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. 2020. Patient Cohort and Their  
681 Implications. *medRxiv.* <https://doi.org/10.1101/2020.03.30.20047365>.
- 682 15. Wu F, Liu M, Wang A, Lu L, Wang Q, Gu C, et al. 2020. Evaluating the Association of  
683 Clinical Characteristics with Neutralizing Antibody Levels in Patients Who Have  
684 Recovered from Mild COVID-19 in Shanghai, China. *JAMA Intern Med.* 180:1356–62.
- 685 16. Robbiani DF, Gaebler C, Frauke M, Lorenzi JC, Wang Z, Cho A, et al. 2020. Convergent  
686 Antibody Responses to SARS-CoV-2 in Convalescent Individuals. *Nature.* 584:437–42.
- 687 17. Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, et al. 2020.  
688 Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 Spike

- 689 protein for neutralization assays. bioRxiv. 10.1101/2020.04.20.051219.
- 690 18. Neerukonda SN, Vassell R, Herrup R, Liu S, Wang T, Takeda K, et al. 2020.
- 691 Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization
- 692 assay using 293T cells with stable expression of ACE2 and TMPRSS2. bioRxiv.
- 693 <https://doi.org/10.1101/2020.12.26.424442>.
- 694 19. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. 2020. Establishment and validation of a
- 695 pseudovirus neutralization assay for SARS-CoV-2. *Emerg Microbes Infect.* 9:680–6.
- 696 20. Case JB, Rothlauf PW, Chen RE, Liu Z, Zhao H, Kim AS, et al. 2020. Neutralizing
- 697 antibody and soluble ACE2 inhibition of a replication-competent VSV- SARS-CoV-2 and
- 698 a clinical isolate of SARS-CoV-2. bioRxiv. <https://doi.org/10.1101/2020.05.18.102038>.
- 699 21. Vandergaast R, Carey T, Reiter S, Lech P, Gnanadurai C, Tesfay M, et al. 2020.
- 700 Development and validation of IMMUNO-COV<sup>TM</sup>: a high-throughput clinical assay for
- 701 detecting antibodies that neutralize SARS-CoV-2. bioRxiv.
- 702 <https://doi.org/10.1101/2020.05.26.117549>.
- 703 22. Dieterle ME, Haslwanter D, Bortz RH, Wirchnianski AS, Lasso G, Vergnolle O, et al.
- 704 2020. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2
- 705 Spike-Mediated Cell Entry and Its Inhibition. *Cell Host Microbe.* 28:486-96.
- 706 23. Hoffmann M, Kleine-weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. 2020.
- 707 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a
- 708 Clinically Proven Article SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and
- 709 Is Blocked by a Clinically Proven Protease Inhibitor. *Cell.* 181:1–10.

- 710 24. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Velesler D. 2020. Structure,  
711 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell*. 180:1–12.
- 712 25. Wan Y, Shang J, Graham R, Baric RS, Li F. 2020. Receptor Recognition by the Novel  
713 Coronavirus from Wuhan : an Analysis Based on Decade-Long Structural Studies of  
714 SARS Coronavirus. *J Virol*. 94:e00127-20.
- 715 26. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. 2020. Characterization of spike glycoprotein  
716 of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nat*  
717 *Commun*. 11:1-12.
- 718 27. Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al.  
719 2020. Potent neutralizing antibodies from COVID-19 patients define multiple targets of  
720 vulnerability. *Science*. 369:643–50.
- 721 28. Legros V, Denolly S, Vogrig M, Boson B, Rigaille J, Pillet S, et al. 2020. A longitudinal  
722 study of SARS-CoV-2 infected patients shows high correlation between neutralizing  
723 antibodies and COVID-19 severity. *medRxiv*.  
724 <https://doi.org/10.1101/2020.08.27.20182493>.
- 725 29. Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, et al. 2020. Potent Neutralizing  
726 Antibodies Directed to Multiple Epitopes on SARS-CoV-2 Spike. *BioRxiv*.  
727 <https://doi.org/10.1101/2020.06.17.153486>.
- 728 30. Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, et al. 2020. Potent Neutralizing Antibodies  
729 against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of  
730 Convalescent Patients' B Cells. *Cell*. 182:73–84.

- 731 31. Yuan M, Liu H, Wu NC, Wilson IA. 2020. Recognition of the SARS-CoV-2 receptor  
732 binding domain by neutralizing antibodies. *Biochem Biophys Res Commun.*  
733 <https://doi.org/10.1016/j.bbrc.2020.10.012>.
- 734 32. Liu L, To KK-W, Chan K-H, Wong Y-C, Zhou R, Kwan K-Y, et al. 2020. High  
735 neutralizing antibody titer in intensive care unit patients with COVID-19. *Emerg Microbes*  
736 *Infect.* 9:1–30.
- 737 33. Zost SJ, Gilchuk P, Chen RE, Case JB, Reidy JX, Trivette A, et al. 2020. Rapid isolation  
738 and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-  
739 CoV-2 spike protein. *Nat Med.* 26: 1422-7.
- 740 34. Chen P, Nirula A, Heller B, Gottlieb RL, Joseph B, Morris J, et al. 2021. SARS-CoV-2  
741 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. *N Engl J Med.*  
742 384:229–37.
- 743 35. Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, et al. 2020. Studies in  
744 humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.  
745 *Science.* 1014:1010–4.
- 746 36. Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. 2020. Antibody  
747 cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with  
748 individual antibodies. *Science.* 1018:1014–8.
- 749 37. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. 2021. REGN-  
750 COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. *N Engl J Med.*  
751 384: 238-51.


- 752 38. Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, et al.  
753 2020. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in  
754 a non-human primate model of SARS-CoV-2 infection. bioRxiv.  
755 <https://doi.org/10.1101/2020.09.30.318972>.
- 756 39. Oguntuyo KY, Stevens CS, Hung CT, Ikegame S, Acklin JA, Kowdle SS, et al. 2020.  
757 Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus  
758 neutralization assay allows for cross-cohort comparisons of COVID-19 sera. medRxiv.  
759 <https://doi.org/10.1101/2020.08.13.20157222>.
- 760 40. Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VM, et al. 2020.  
761 Severe Acute Respiratory Syndrome Coronavirus 2–Specific Antibody Responses in  
762 Coronavirus Disease Patients. *Emerg Infect Dis J.* 26:1478-88.
- 763 41. Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus ADME, et al. 2020. A  
764 human monoclonal antibody blocking SARS-CoV-2 infection. *Nat Commun.* 11:1–6.
- 765 42. Perera RAPM, Mok CKP, Tsang OTY, Lv H, Ko RLW, Wu NC, et al. 2020. Serological  
766 assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020.  
767 *Eurosurveillance.* 2:1–9.
- 768 43. Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, et al. 2020. A  
769 simple protein-based surrogate neutralization assay for SARS-CoV-2. *JCI Insight.*  
770 5:e142362.
- 771 44. Tan CW, Chia WN, Qin X, Liu P, Chen MI-C, Tiu C, et al. 2020. A SARS-CoV-2  
772 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike  
773 protein–protein interaction. *Nat Biotechnol.* 38: 1073-8.

- 774 45. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. 2021. Immunological  
775 memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*. 4063:1–23.
- 776 46. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. 2020. Robust  
777 neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science*. 370:1227–  
778 30.
- 779 47. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IAJ, James CD, et al. 2005.  
780 Rescue and propagation of fully retargeted oncolytic measles viruses. *Nat Biotechnol*.  
781 23:209–14.
- 782 48. Ammayappan A, Nace R, Peng K-W, Russell SJ. 2013. Neuroattenuation of Vesicular  
783 Stomatitis Virus through Picornaviral Internal Ribosome Entry Sites. *J Virol*. 87:3217–28.
- 784 49. Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel SK, Murray J, et al. 2020. Severe Acute  
785 Respiratory Syndrome Coronavirus 2 from Patient with 2019 Novel Coronavirus Disease,  
786 United States. *Emerg Infect Dis*. 26:1266–73.
- 787

788

## FIGURES


FIG. 1



789


790 **Figure 1:** Overview of the IMMUNO-COV™ v2.0 Assay. A VSV expressing SARS-CoV-2 spike  
791 and firefly luciferase (VSV-SARS2-Fluc) is incubated with test sera or plasma. In the absence of  
792 SARS-CoV-2-neutralizing antibodies (top) the virus retains infectivity and infects Vero-ACE2  
793 monolayers. If the test sample contains SARS-CoV-2-neutralizing antibodies (bottom), the  
794 antibodies inhibit infection by blocking cell entry. As virus replication proceeds, infected cells  
795 express luciferase, which is used to quantitate virus-infection. High luciferase signal means the  
796 test sample did not neutralize the virus, while decreased luciferase indicates the presence of SARS-  
797 CoV-2-neutralizing antibodies.

**FIG. 2**



799 **Figure 2:** *Generation and Characterization of VSV-SARS2-Fluc.* A) Schematic Representation of  
800 the VSV-SARS2-Fluc Genome. The location of the VSV N, P, M (M51R), and L genes are shown.  
801 In place of VSV-G a codon optimized SARS-CoV-2 spike gene with a 19 amino acid C-terminal  
802 (CT) deletion ( $\Delta 19$ CT) is substituted. TM is transmembrane domain. Firefly luciferase (Fluc) is  
803 inserted as an additional transcriptional element between S- $\Delta 19$ CT and L. Not drawn to scale. B)  
804 Immunoblot Analysis. VSV-SARS2-Fluc or VSV-GFP control virus ( $5 \times 10^5$  total pfu) or spike  
805 control from lysates of cells overexpressing SARS-CoV-2 spike were subjected to immunoblot  
806 analysis using  $\alpha$ -SARS-CoV-2 spike antibody (left) and  $\alpha$ -VSV-G antiserum (right). Arrows  
807 indicate the full-length S1/S2 variant and cleaved S2 variant of spike and the VSV-G proteins. C)  
808 Infection of Cell Monolayers. Vero-ACE2 or BHK-21 cell monolayers were infected with VSV-  
809 SARS2-Fluc, control VSV-Fluc, or mock-infected. Images were taken 48 h post infection at 100X  
810 magnification. D-E) Replication Curves. Vero-ACE2 or BHK-21 cell monolayers were infected  
811 as in panel C and the virus titers from culture supernatants collected at the indicated times post  
812 inoculation were determined. F-G) Luciferase Activity. Vero-ACE2 or BHK-21 cells were  
813 infected with VSV-SARS2-Fluc, control VSV-Fluc, or mock-infected in 96-well plates, and at the  
814 indicated times luciferase activity was measured. H-K) Flow Cytometry. Expression of ACE2 (H  
815 and I) and TMPRSS2 (J and K) were measured in Vero and Vero-ACE2 cells by flow cytometry  
816 using  $\alpha$ -ACE2 or  $\alpha$ -TMPRSS2, respectively. Controls were secondary antibody only.


**FIG. 3**



817

818 **Figure 3:** *Inhibition of VSV-SARS2-Fluc by Monoclonal Antibodies and Convalescent Sera.* A) 819 Infectivity of Different Vero Cell Lines. VSV-SARS2-Fluc was incubated with 2 or 0.2  $\mu\text{g/mL}$  of 820 monoclonal anti-SARS-CoV-2 spike antibody mAb10914 in pooled seronegative sera, or pooled 821 seronegative sera alone (negative matrix). After 30 min, virus mixes were overlaid onto Vero, 822 Vero-ACE2, or Vero-ACE2/TMPRSS2 cells. Luciferase activity was measured after an additional 823 24 h. Values represent the average (mean) RLU  $\pm$  standard deviation. B) Optimization of Cell 824 Density. The indicated numbers of Vero-ACE2 cells were seeded in 96-well plates. The following 825 day, virus mixes as described in panel A were overlaid onto the cell monolayers. Luciferase 826 activity was measured after an additional 24 h. Values represent the average (mean) RLU  $\pm$  827 standard deviation. C) Neutralization by Convalescent Sera. VSV-SARS2-Fluc was incubated 828 with pooled seronegative sera at 1:80 dilution or sera samples from 11 donors (6 seronegative, 5 829 seropositive for anti-SARS-CoV-2 antibodies by ELISA assay) at 1:80 dilution. After 30 min, 830 virus/sera mixes were overlaid onto Vero-ACE2 cells. Luciferase activity was measured after an 831 additional 24 h. Values represent average (mean) luciferase activity relative to the pooled 832 seronegative sera sample control  $\pm$  standard deviation.

**FIG. 4**



833

834 **Figure 4: Assay Performance of VSV-SARS2-Fluc.** A) Susceptibility of Virus to Antibody

835 Neutralization. The indicated amounts (plaque forming units; pfu) of VSV-SARS2-Fluc were

836 incubated with 2 or 0.2 µg/mL anti-SARS-CoV-2 spike monoclonal antibody mAb10914, a SARS-

837 CoV-2 seropositive plasma sample at 1:80 dilution, or pooled seronegative serum (negative matrix,

838 1:80). After 30 min, virus mixes were overlaid onto Vero-ACE2 cells, and luciferase activity was


839 measured after an additional 24 h. Values represent the average (mean) luciferase activity relative

840 to the negative matrix control ± standard deviation. B) Consistency of Virus Lots. Varying amounts

841 (pfu) of two different lots (A and B) of VSV-SARS2-Fluc were incubated with the indicated


842 concentrations of mAb10914. Luciferase activity was measured after an additional 24 h. Values  
843 represent the average (mean) RLU  $\pm$  standard deviation. C-D) Virus Stability. Aliquots of VSV-  
844 SARS2-Fluc were removed from the freezer, thawed, and either used immediately for assay  
845 (Immediate use) or stored at either room temperature or on ice for the indicated time (h). For assay,  
846 300 pfu of VSV-SARS2-Fluc was incubated with 0.154 (QC-High) or 0.031 (QC-Low)  $\mu$ g/mL of  
847 anti-SARS-CoV-2 spike monoclonal antibody mAb10922 in pooled seronegative sera, or in  
848 pooled seronegative sera alone (Neg. Control). After 30 min, virus mixes were overlaid onto Vero-  
849 ACE2 cells and luciferase activity was measured after an additional 24 hours. Values represent the  
850 average (mean) RLU  $\pm$  standard deviation.

**FIG. 5**



852 **Figure 5:** *Effect of Sample Matrix on Assay Performance.* A-B) Effect of Heat-Inactivation of Sera  
853 or Plasma. Matched sera (A) and sodium-heparin plasma (B) samples from 20 donors (11  
854 seronegative, 9 seropositive for anti-SARS-CoV-2 antibodies by ELISA assay) were split and  
855 either incubated on ice or at 56°C for 30 min. Following incubation, plasma samples were clarified  
856 by centrifugation. Samples were then incubated at 1:80 dilution with VSV-SARS2-Fluc. Pooled  
857 seronegative sera or plasma were used as assay controls. After 30 min, virus mixes were overlaid  
858 onto Vero-ACE2 cells, and after an additional 24 h, luciferase activity was measured. Values  
859 represent the average (mean) luciferase activity relative to the pooled seronegative matrix control  
860  $\pm$  standard deviation. C-F) Characterization of Matrix Interference. Seronegative sera (C, n=40),  
861 sodium-heparin plasma (D, n=40), ACD plasma (E, n=26), or K2-EDTA plasma (F, n=49) samples  
862 were serially diluted as indicated and incubated with VSV-SARS2-Fluc. Virus mixed with media  
863 only was used as a control. After 30 min, virus mixes were overlaid onto Vero-ACE2 cells, and  
864 after an additional 24 h, luciferase activity was measured. Values represent the average (mean)  
865 luciferase activity relative to the media control  $\pm$  standard deviation.


**FIG. 6**



866

867 **Figure 6:** *Establishment of a Standard Curve for Titer Calculations.* A) Antibody-Specific  
868 Neutralization of VSV-SARS2-Fluc. The indicated concentrations of anti-SARS-CoV-2 spike  
869 monoclonal antibodies mAb10914 or mAb10922 or isotype control antibody were incubated with  
870 VSV-SARS2-Fluc. After 30 min, virus mixes were overlaid onto Vero-ACE2 cells, and luciferase  
871 activity was measured after an additional 24 h. Values represent the average (mean) luciferase  
872 activity relative to the media control  $\pm$  standard deviation. B) Standard Curve Performance. VSV-  
873 SARS2-Fluc was incubated with 0.8, 0.4, 0.2, 0.1, 0.05, or 0.025  $\mu\text{g}/\text{mL}$  (corresponding to the  
874 indicated equivalent VNTs) of mAb10914 or negative pooled sera alone. After 30 min, virus mixes  
875 were overlaid onto Vero-ACE2 cells, and luciferase activity was measured after an additional 24  
876 h. Values represent average (mean) luciferase activity relative to the pooled negative sera control  
877  $\pm$  standard deviation from 242 unique assay runs. C) Limit of Detection. Five different  
878 seronegative sera samples (at 1:80 dilution) were spiked with anti-SARS-CoV-2 spike monoclonal  
879 antibody mAb10914 at 0.01, 0.02, 0.04, 0.06, 0.08, and 0.1  $\mu\text{g}/\text{mL}$  (corresponding to the indicated  
880 equivalent VNTs), and incubated with VSV-SARS2-Fluc. VSV-SARS2-Fluc incubated with  
881 unspiked sera samples (Neg) or media alone were included as controls. After the 30 min  
882 incubation, virus mixes were overlaid onto Vero-ACE2 cells, and luciferase activity was measured  
883 after an additional 24 h. Box and whisker diagrams display the interquartile range in the box, with  
884 the center line representing the median for the data set and whiskers representing the lower 5%  
885 and upper 95% value. Values are based on a total of 12 different assay runs performed on three  
886 separate days by six analysts using two different virus lots.


**FIG. 7**



887

888 **Figure 7: Inter-Assay Variability of Standards and Controls.** Standards consisting of monoclonal  
889 anti-SARS-CoV-2 spike antibody mAb10914 at 0.8, 0.4, 0.2, 0.1, 0.05, and 0.025  $\mu\text{g}/\text{mL}$  in media,  
890 and QC High and QC Low controls consisting of 0.154 and 0.031  $\mu\text{g}/\text{mL}$  antibody mAb10922 in  
891 pooled seronegative sera were incubated with VSV-SARS2-Fluc. Pooled seronegative sera alone  
892 was used as a negative control. After 30 min, virus mixes were overlaid onto Vero-ACE2 cells,  
893 and luciferase activity was read after an additional 24 h. A total of 207 assay runs were performed  
894 over five days, by five analysts, using two different virus lots. Box plot represents the 25<sup>th</sup> to 75<sup>th</sup>  
895 percentile of the data with the line representing the media titer equivalent (VNT) value. Whiskers  
896 display the minimum and maximum values.


**FIG. 8**



897

898 **Figure 8:** *Correlation of Virus Neutralizing Units to PRNT50%.* 58 SARS-CoV-2 seropositive  
899 sera samples were assayed using IMMUNO-COV™ v2.0 starting at a 1:80 dilution. Established  
900 controls, including a standard curve (0.8, 0.4, 0.2, 0.1, 0.05, and 0.025  $\mu\text{g}/\text{mL}$  mAb10914 in  
901 media), were included on each assay plate. The IMMUNO-COV™ v2.0 titer (VNT) was  
902 determined using the standard curve, where one VNT equals the concentration of mAb10914  
903 multiplied by 400. All samples were subjected to PRNT using a clinical isolate of SARS-CoV-2.  
904 Statistical comparison of VNT relative to PRNT50% was performed using Spearman's rank order  
905 correlation analysis as both datasets had a non-gaussian distribution ( $p < 0.0001$ ).


**FIG. 9**



906

907 **Figure 9:** *The Strength of Neutralizing Antibody Responses Correlates to Disease Severity.* As  
908 part of assay validation (Table 2), neutralizing antibody titers were determined for 46 donors who  
909 self-reported COVID-19 disease symptoms at least two weeks prior to sample donation. Disease  
910 symptoms were classified as severe (acute respiratory distress or pneumonia), moderate (shortness  
911 of breath), mild (fever, feverish, cough, chills, myalgia, rhinorrhea, sore throat, nausea/vomiting,  
912 headache, abdominal pain, or diarrhea), or none (asymptomatic). The graph indicates the titer value  
913 (VNT) for each donor grouped based on disease symptoms. Bars represent the average (mean) titer  
914 for each group. Differences in antibody titers based on disease severity were not statistically  
915 significant (n.s.) by one-way ANOVA ( $p = 0.1904$ ).

**FIG. 10**



917 **Figure 10:** Durability of neutralizing antibody responses. A-C) Samples were collected from  
918 donors in April and October 2020 (n=13). Neutralizing antibody levels were measured using  
919 IMMUNO-COV™ v2.0 (A), PRNT assay (B), or the c-PASS SARS-CoV-2 neutralization  
920 antibody detection kit (C), which is a binding assay that utilizes the SARS-CoV-2 spike RBD  
921 domain. The reductions in antibody titers were statistically significant for IMMUNO-COV™ v2.0  
922 and PRNT assay, but not for the sVNT binding assay ( $p = 0.0007$ ,  $0.0004$ , and  $0.4669$ , respectively,  
923 from paired T test).

924

## **TABLES**

*Table 1: Assay Linearity*

<b>Standard Nominal Value<sup>1</sup></b>	<b>ST1 320</b>	<b>ST2 160</b>	<b>ST3 80</b>	<b>ST4 40</b>	<b>ST5 20</b>	<b>ST6 10</b>
Mean Value	278.0	167.3	80.3	39.3	20.4	10.7
SD	23.7	21.4	8.7	3.1	1.7	1.3
%CV	8.5	12.8	10.8	8.2	8.1	12.0
%RE	-13.1	4.6	0.4	-1.9	1.9	7.3
% in range <sup>2</sup>	59.5	99.2	99.6	100.0	99.4	39.4
Number in range <sup>2</sup>	144	240	241	242	226	95

SD = standard deviation

CV = co-efficient of variation

RE = relative error

<sup>1</sup>Expected VNT value based on concentration of mAb10914 in each standard.

<sup>2</sup>Total *n* from all runs is 242.

925

*Table 2: Assay Specificity and Sensitivity*

	<b>Specificity<sup>1</sup></b>	<b>Sensitivity<sup>2</sup></b>
<b>PRNT50%</b>		
Percentage	100%	93.7%
Sample Agreement	113/113	59/63
<b>PRNT80%</b>		
Percentage	100%	98.4%
Sample Agreement	116/116	59/60

<sup>1</sup>IMMUNO-COV™ v2.0 negative results relative to PRNT/ EUROIMMUN IgG ELISA negative results (samples positive by ELISA but negative by PRNT were considered negative).

<sup>2</sup>IMMUNO-COV™ v2.0 positive results relative to PRNT positive results. Any samples collected from donors previously PCR-positive for SARS-CoV-2, or positive for SARS-CoV-2 antibodies by IMMUNO-COV™ v2.0 or EUROIMMUN IgG ELISA were tested by PRNT assay.

**Table 3: Intra- and Inter-Assay Variability**

<b>QC Level</b>	<b>QC High</b>			<b>QC Low</b>			<b>Matrix Blank</b>
<b>Predicted VNT<sup>1</sup></b>	<b>160</b>			<b>32</b>			<b>0</b>
<b>Precision Criteria</b>	<b>% Response</b>	<b>VNT</b>	<b>Intra-Assay %CV</b>	<b>% Response</b>	<b>VNT</b>	<b>Intra-Assay %CV</b>	<b>Intra-Assay %CV</b>
Mean Value	2.8	208.6	13.3	37.7	29.8	21.4	9.8
SD	1	37.7		11.5	8.6		
%CV	37.8	18.1		30.6	28.8		

SD = standard deviation

CV = co-efficient of variation

*n* = 207

<sup>1</sup>Predicted VNT of QC samples based on concentration of mAb10922 spiked into matrix blank.

*Table 4: Matrix Equivalency*

	<b>Sodium heparin-plasma</b>	<b>ACD-plasma</b>	<b>K2/EDTA-plasma</b>
<b>%RE</b> (relative to sera) <sup>1</sup>	+9.3	-9.8	+24.6

%RE = percent relative error

<sup>1</sup>Consensus VNT titers from the indicated plasma samples were compared to the consensus VNT titer for the matched serum sample.  $n=12$ .

*Table 5: VNT to PRNT50% Conversion*

<b>VNT</b>	<b>PRNT50%</b>
< 32	< 1:40
32 to 40	1:40
41 to 80	1:80
81 to 180	1:160
181 to 400	1:320
401 to 800	1:640
801 to 1600	1:1280
1601 to 2400	1:2560
> 2400	> 1:2560

929

Table 6: Longevity of Neutralizing Antibodies

Donor	IMMUNO-COV™ v2.0 Titer (VNT)			c-PASS Value <sup>1</sup>		
	April <sup>2</sup>	October <sup>3</sup>	Relative titer	April <sup>2</sup>	October <sup>3</sup>	Relative value
1	1652	784	0.47	94	95	1.01
2	1187	320	0.27	84	96	1.14
3	47	< LOD	≤ 0.68	49	35	0.71
4	769	376	0.49	92	92	1.00
5	3030	378	0.12	88	74	0.84
6	1179	246	0.21	91	79	0.87
7	1219	378	0.31	95	84	0.88
8	124	< LOD <sup>4</sup>	≤ 0.26	67	42	0.63
9	894	156	0.17	74	73	0.99
10	102	< LOD <sup>4</sup>	≤ 0.31	62	54	0.87
11	660	195	0.30	91	83	0.91
12	350	68	0.19	52	49	0.94
13	114	418	3.67	45	85	1.89

<sup>1</sup>Samples analyzed using the c-PASS SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit

<sup>2</sup>April samples acquired from donors 2 to 8 weeks following COVID-19 symptoms or diagnosis.

<sup>3</sup>October samples acquired from same donors approximately 6 months after April samples acquired.

<sup>4</sup>Matched ACD-plasma samples were also analyzed and exhibited low-levels of neutralizing antibodies in some assay runs.